NCT03900364 is a NA clinical trial of partial nephrectomy in Carcinoma, Renal Cell, sponsored by Salzburger Landeskliniken.

Who is sponsoring NCT03900364?

NCT03900364 is sponsored by Salzburger Landeskliniken.

What drugs are being tested in NCT03900364?

Interventions in NCT03900364: partial nephrectomy.

What condition does NCT03900364 study?

NCT03900364 studies Carcinoma, Renal Cell, Renal Malignant Tumor, Renal Cyst, Renal Tumor.

Is NCT03900364 still recruiting?

NCT03900364 is currently completed. Last updated 28 September 2021.

Last reviewed 2021-09-28 · How we verify

NCT03900364

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

a Prospective Trial Comparing Robot-assisted Partial Nephrectomy Versus Laparoscopic Partial Nephrectomy

Completed NA Last updated 28 September 2021

What this trial tests

NA trial testing partial nephrectomy in Carcinoma, Renal Cell in 30 participants. Completed in 15 October 2020.

Timeline

3 September 2018

Primary endpoint
15 October 2020

15 October 2020

Quick facts

Lead sponsor	Salzburger Landeskliniken
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	30
Start date	3 September 2018
Primary completion	15 October 2020
Estimated completion	15 October 2020
Sites	1 location across Austria

Drugs / interventions tested

partial nephrectomy

Conditions studied

Carcinoma, Renal Cell — all drugs for Carcinoma, Renal Cell →
Renal Malignant Tumor — all drugs for Renal Malignant Tumor →
Renal Cyst — all drugs for Renal Cyst →
Renal Tumor — all drugs for Renal Tumor →

Sponsor

Salzburger Landeskliniken — full company profile →

Who can join

18 and older, any sex, with Carcinoma, Renal Cell or Renal Malignant Tumor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In this trial the investigators want to examine and compare oncological and surgical outcomes of two surgical techniques in a prospective, randomised, single-blind trial. Therefore the investigators are going to include 30 patients with a renal mass who need surgical treatment. When they fulfill the inclusion criteria they get randomised either for robot-assisted partial nephrectomy or laparoscopic partial nephrectomy. Primary endpoint is the oncological outcome (residual tumor classification, TNM classification), secondary endpoints are operation time, time of ischemia, blood loss, pain after surgery, kidney function, complications and hospital stay.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Robotic Versus Laparoscopic Partial Nephrectomy: A Prospective, Randomised Trial Comparing Two Surgical Techniques
Oberhammer L, Lusuardi L, Kunit T, Griessner H, et al · · 2022 · DOI 10.21203/rs.3.rs-2293390/v1

Verify or expand the search:

Other trials of partial nephrectomy

Trials testing the same drug.

NCT05168761 — Complications Associated With Partial Nephrectomy for Renal Cancer · completed

Other recruiting trials for Carcinoma, Renal Cell

Currently open trials in the same condition.

NCT07405164 — Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043) · Phase 3 · recruiting
NCT07227415 — Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Antica · Phase 1, PHASE2 · recruiting
NCT06222593 — Study to Evaluate the Safety and Efficacy of Bicalutamide in Combination With Sunitinib in Patients With TKIs-resistant · Phase 1, PHASE2 · recruiting
NCT07166445 — Deep Learning for Automated Discrimination Between Stage T1-T2 and T3 Renal Cell Carcinoma on Contrast-Enhanced CT · recruiting
NCT06676527 — Vorolanib in the Second-line Treatment of Patients With Unresectable or Metastatic Renal Cell Carcinoma · recruiting

Other Salzburger Landeskliniken trials

Trials by the same sponsor.

NCT06754137 — Assessing AI-Supported Fracture Detection in Emergency Care Units · NA · recruiting
NCT06402487 — Propionic Acid in Multiple Sclerosis · Phase 2, PHASE3 · completed
NCT06579911 — Combining High-frequency Micro-ultrasound and Multiparametric MRI Target Biopsy for Detecting Prostate Cancer · NA · recruiting
NCT05024435 — Evaluation of Semi-rigid and Flexible Catheters for Less Invasive Surfactant Administration in Preterm Infants · NA · completed
NCT03503721 — Bipolar Transurethral Enucleation (BipolEP) vs Bipolar Transurethral Resection of the Prostate · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03900364 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Salzburger Landeskliniken
Last refreshed: 28 September 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03900364.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing